Drug intelligence / Profile preview

[111In]In-DOTA-ZROR1

Development stage
Preclinical
Lead developer
KTH Royal Institute of Technology
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Recombinant Proteins and Enzymes, Peptides
Administration
Intravenous
01

Overview

[111In]In-DOTA-ZROR1 (also known as [111In]In-DOTA-ZROR1:A10) is a first-in-class radiolabeled affibody-based imaging agent designed for single-photon emission computed tomography (SPECT) visualization of tumor-associated receptor tyrosine kinase-like orphan receptor 1 (ROR1) expression. The agent consists of a high-affinity ROR1-targeting affibody molecule, ZROR1 (specifically the ZROR1:A10 clone), conjugated to the chelator DOTA and radiolabeled with the gamma-emitting radionuclide indium-111 ([111In]). ZROR1 binds with high affinity to both human and murine ROR1 (Kd of 4 nM and 2 nM, respectively). Preclinical evaluations in ROR1-expressing tumor models (such as MDA-MB-468 breast cancer xenografts) have demonstrated rapid blood clearance, high tumor-to-blood ratios, and specific, saturable tumor uptake, highlighting its potential as a noninvasive diagnostic tool for patient stratification and treatment monitoring in ROR1-targeted therapies.

Other names
[111In]In-DOTA-ZROR1:A10[111In]In-ZROR1:A10DOTA-ZROR1:A10ZROR1ZROR-1ZROR 1ZROR1-DOTAZROR-1-DOTAZROR 1-DOTAZROR1:A10ZROR1:A10-DOTA
02

Identity

Drug type
Radiopharmaceuticals
Modality
Recombinant Proteins and EnzymesPeptidesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesGamma Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
breast cancer and precursor lesionsPreclinicalActive
colorectal cancer (CRC) and precursor lesionsPreclinicalActive
ovarian cancer and premalignant lesionsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • KTH Royal Institute of TechnologyLead developer
07

Competitive landscape

Drugs on the same target
22
Drugs in the lead indication
1,053

Lead indication: breast cancer and precursor lesions

Most advanced in the lead indication

  1. cyclophosphamideApproved
  2. epirubicinApproved
  3. eribulinApproved
  4. fludeoxyglucose f 18Approved
  5. fluorouracilApproved

Beyond the preview

Go deeper on [111In]In-DOTA-ZROR1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [111In]In-DOTA-ZROR1.

Work on [111In]In-DOTA-ZROR1? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call